Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Expédition mondial!
Plus d'info »
CYP2B6, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes. De plus, nous expédions CYP2B6 Kits (11) et CYP2B6 Protéines (3) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 54 products:
Human Polyclonal CYP2B6 Primary Antibody pour EIA, IF - ABIN951782 : Cabrera Figueroa, Fernández de Gatta, Hernández García, Domínguez-Gil Hurlé, Bustos Bernal, Sepúlveda Correa, García Sánchez: The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. dans Therapeutic drug monitoring 2010 (PubMed) Show all 4 references for ABIN951782
Human Polyclonal CYP2B6 Primary Antibody pour ELISA, WB - ABIN1534383 : Yamano, Nhamburo, Aoyama, Meyer, Inaba, Kalow, Gelboin, McBride, Gonzalez et al.: cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression ... dans Biochemistry 1990 (PubMed) Show all 3 references for ABIN1534383
Human Monoclonal CYP2B6 Primary Antibody pour FACS, IF - ABIN2455580 : Sim, Nam, Lee, Lee, O, Joo, Liu, Han, Ki, Jeong, Lee, Lee: Selective induction of hepatic cytochrome P450 2B activity by leelamine in vivo, as a potent novel inducer. dans Archives of pharmacal research 2015 (PubMed) Show all 2 references for ABIN2455580
Human Polyclonal CYP2B6 Primary Antibody pour IF, IHC (p) - ABIN655056 : Bunten, Liang, Pounder, Seneviratne, Osselton: OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. dans Clinical pharmacology and therapeutics 2010 (PubMed) Show all 2 references for ABIN655056
Cow (Bovine) Polyclonal CYP2B6 Primary Antibody pour WB - ABIN2777002 : Ekhart, Doodeman, Rodenhuis, Smits, Beijnen, Huitema: Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. dans Pharmacogenetics and genomics 2008 (PubMed)
It has been established that cytochrome P4502B6 (CYP2B6) is the major isoform catalyzing both ketamine N-demethylation and ketamine metabolism overall in vitro at therapeutic concentrations and clinically.
polymorphism c.516G>T in the CYP2B6 gene and BMI affect the metabolism rate of propofol and may play an important role in the optimisation of propofol anaesthesia
his cross-sectional, pharmacogenetic candidate, gene pilot study recruited 75 patients having minor elective outpatient surgeries. EP was measured with the Clinician Administered Dissociative State Scale. Genetic association of CYP2B6*6 and GRIN2B (Montrer GRIN2B Anticorps) (rs1019385 and rs1806191) single-nucleotide polymorphisms and ketamine-induced EP occurrence and severity were tested using logistic and linear regression.
Data suggest that A785G CYP2B6 gene polymorphisms and specific CYP2B6 haplotypes may be a risk factor for the pathogenesis of AML (Montrer RUNX1 Anticorps), especially secondary AML (Montrer RUNX1 Anticorps) as well as for the induction of AML (Montrer RUNX1 Anticorps) chromosomal aberrations.
Results show that CYP2B6 slow metabolizer genotypes were significantly associated with efavirenz induced central nervous system symptoms.
The possible influence of CYP2B6 c.516G>T genetic variant on propofol dose.
Around 450 and 250 mg daily doses might meet EFV dosing needs of HIV-TB infected Ugandans in general and CYP2B6*6/*6 genotypes, respectively.
CYP2B6 polymorphisms were associated with lower and higher plasma concentrations in pregnant and postpartum women.
Analysis of gene-gene interactions with CYP2B6 was particularly useful to reinforce the role of MRP4 (Montrer ABCC4 Anticorps) and to reveal unknown associations, such as that of DRD3 (Montrer DRD3 Anticorps).
POR (Montrer POR Anticorps) rs2868177 and CYP2B6*6 variants contribute to the interindividual variability in human CYP2B6 activity, which may affect the disposition and interaction of other CYP2B6 substrate drugs
This gene, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to metabolize some xenobiotics, such as the anti-cancer drugs cyclophosphamide and ifosphamide. Transcript variants for this gene have been described\; however, it has not been resolved whether these transcripts are in fact produced by this gene or by a closely related pseudogene, CYP2B7. Both the gene and the pseudogene are located in the middle of a CYP2A pseudogene found in a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.
cytochrome P450 2B6 , cytochrome P450 CYP2B30 , cytochrome P450, family 2, subfamily B, polypeptide 6 , cytochrome P450 PBD-2 , cytochrome P450, family 2, subfamily B, polypeptide 11 , CYPIIB3 , cytochrome P450 2B3 , cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6 , cytochrome P450IIB3 , 1,4-cineole 2-exo-monooxygenase , cytochrome P450 IIB1